Core Takeda portfolio shrunk by 75% in 18 years

Development of “Core Takeda” patent portfolio, originally applied for by Takeda, excluding acquisitions.

After already having a taste of acquisitions with the recent takeovers of IDM and Millennium Pharma, Takeda followed this with a spate of other acquisitions building both a wider-reaching company and a stronger innovation platform. The first New Takeda acquisition was Nycomed (in 2011) followed by URL Pharma (2012), Multilaba (2012), Ariad Pharma (2017) and TiGenix (2018). A number of these providing a significant boost to the Takeda patent portfolio, but the biggest would be the recently discussed acquisition of Shire for €53bn.


Transformation into the New Takeda

Development of the New Takeda, separating portfolio of acquired companies from the “Core Takeda” portfolio. Related companies for reference (AstraZeneca, Pfizer & Bristol-Myers Squibb)


The contribution to the New Takeda which comes from patents originally applied for by Takeda themselves, “Core Takeda”, is smaller than that from their two biggest acquisitions, Millennium and Shire (expected). Illustrating what a turning point this transition has been for the company. Through this process of carefully portfolio pruning and considered acquisition Takeda has transformed itself from a wilting flower to an IP powerhouse. In total, over the past 18 years, Takeda has lost or pruned 3000 patent families, changing their Competitive Impact from 1, the PatentSight database average, to 2.9. Whilst Takeda’s acquisitions have increased the portfolio to around 1800 patent families further improving the Competitive Impact to 3.6.

With the field of Pharmaceuticals being dominated by big companies, Takeda’s acquisitions have turned a spate of fringe players into a contender in the international market. Only time will tell if the New Takeda will continue in its rise and challenge the giants of the industry, or if it will languish in its success.